For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
We use cookies to make our site as useful as possible.
Our Cookie Policy explains how you can opt-out of the cookies we use.
If you continue without changing your cookie settings, we'll assume you’re happy with this.
The anti-CD31 antibody is commonly used in angiogenesis research and work that requires the identification of endothelium by immunohistochemistry (IHC). Using human and mouse kidney samples, we asked an independent collaborator to compare our anti-CD31 RabMAb® rabbit monoclonal (ab76533) against the leading monoclonal alternatives.
Results
Our anti-CD31 antibody outperformed the competition:
Citric acid antigen retrieval method
Abcam anti-CD31 (ab76533) | Competitor X | Competitor Y |
1/400 dilution | 1/50 dilution | 1/50 dilution |
Tris-EDTA antigen retrieval method
Abcam anti-CD31 (ab76533) | Competitor X | Competitor Y |
1/200 dilution | 1/50 dilution | 1/50 dilution |
Testing conditions
A series of dilutions was conducted to determine the optimal concentration of each primary antibody. The secondary antibodies were biotinylated and used at a 1/300 dilution. Blocking solution was 2% BSA in 1x TBS and azide (pH7.6). Optimal antigen retrieval methods were found to be tris-EDTA (pH9) or citric acid (pH6).
Try our anti-CD31 RabMAb® rabbit monoclonal (ab76533) in a 10 µL trial size